Meeting
2024 ASCO Annual Meeting
A phase I open-label study of a novel IL-2Rβ/γ cytokine agonist, LTC004, in patients with advanced or metastatic solid tumors.
Authors
Jifang Gong
Beijing Cancer Hospital, Beijing, China
Jifang Gong , Lin Shen , Aimin Zang , Huan Zhou , Jie Tang , Dan Liu , Youchao Jia , Beibei Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Clinical Trial Registration Number
NCT05666635
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2652)
DOI
10.1200/JCO.2024.42.16_suppl.2652
Abstract #
2652
Poster Bd #
131
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Preliminary results of surufatinib (Suru) plus standard chemotherapy (ChT) as second line (2L) treatment of advanced gastric cancer (aGC): A single-arm, phase 2 clinical trial.
First Author: Ting Han
Poster
2023 ASCO Annual Meeting
Efficacy of eribulin administered in combination with an immune checkpoint inhibitor (ICI) and anlotinib as salvage treatment for patients (pts) with advanced adult soft tissue sarcoma (STS).
First Author: Xi Guo
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla